Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Virpax Pharmaceuticals, Inc.

Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Announces Pricing of $2.25 Million Public Offering
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2023 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces Leadership Transition
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports 2022 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Tickers VRPX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.